Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells

11 Nov 2013

Abstract excerpt

Tivantinib has been described as a potent and highly selective inhibitor of the receptor tyrosine kinase c-MET and is currently in advanced clinical development for several cancers including non-small cell lung cancer (NSCLC). However, recent studies suggest that tivantinib's anticancer properties are unrelated to c-MET inhibition. Consistently, in determining tivantinib's activity profile in a broad panel of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Liver physiology and pathology
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24215125
DOI: 10.1021/cb400660a

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer CellsPMID 24215125Read ↗

Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemiaSemantic proximity Read ↗

Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non‐small‐cell lung cancer cell linesSemantic proximity Read ↗

GSK3beta: role in therapeutic landscape and development of modulators.Semantic proximity Read ↗

Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016-2020).Semantic proximity Read ↗

Glycogen synthase kinase GSK3α promotes tumorigenesis by activating HIF1/VEGFA signaling pathway in NSCLC tumorSemantic proximity Read ↗

Glycogen synthase kinase 3beta induces apoptosis in cancer cells through increase of survivin nuclear localization.Semantic proximity Read ↗

Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity In VitroSemantic proximity Read ↗

Structural Insights into the Development of Inhibitors Against Cancer-Specific Mutations of PI3Kα.Semantic proximity Read ↗

Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.Semantic proximity Read ↗

Deregulated GSK3 Sustains Gastrointestinal Cancer Cells Survival by Modulating Human Telomerase Reverse Transcriptase and TelomeraseSemantic proximity Read ↗

Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind METSemantic proximity Read ↗

Exploring a kinase inhibitor targeting PI3KCA mutant cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.